South Korea Radiopharmaceuticals Market Size, Share, and COVID-19 Impact Analysis, By Type (Diagnostic and Therapeutic) and By Application (Neurology, Cardiology, Oncology, and Others), and South Korea Radiopharmaceuticals Market Insights, Industry Trend, Forecasts to 2035.

South Korea Radiopharmaceuticals Market Insights Forecasts to 2035

• The South Korea Radiopharmaceuticals Market Size Was Estimated at USD 0.190 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.24% from 2025 to 2035
• The South Korea Radiopharmaceuticals Market Size is Expected to Reach USD 0.454 Billion by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Radiopharmaceuticals Market Size is anticipated to reach USD 0.454 Billion by 2035, growing at a CAGR of 8.24% from 2025 to 2035. The market for radiopharmaceuticals in South Korea is currently expanding significantly, mostly due to the increased demand for precise diagnostic techniques and the rising prevalence of chronic illnesses.

Market Overview

The manufacturing, distribution, and application of pharmaceutical preparations containing radioactive isotopes, mainly for nuclear medicine diagnostic and therapeutic applications, are all included in the radiopharmaceuticals market. These medications sometimes referred to as radioactive or radioisotope-conjugated medications, are used to evaluate physiological processes, examine interior structures, and target certain tissues for therapeutic action. When used with imaging methods such as PET and SPECT, radiopharmaceuticals aid in determining the precise location of illnesses, facilitating prompt and precise diagnosis. By enabling non-invasive disease lesion monitoring, radiopharmaceuticals enable precise patient classification and individualized treatment regimens. Better treatment of chronic illnesses, such as cancer, heart disease, and neurological disorders, results from early and precise diagnosis. The market is mostly driven by the rising prevalence of cancer and the creation of tailored treatments, such as those that use therapeutic radionuclides. By providing tailored therapy and accurate imaging, radiopharmaceuticals enhance patient outcomes. Governments are making significant investments in cancer research, nuclear medicine, and the creation of novel radiopharmaceuticals. Novel medications are being introduced more quickly thanks to streamlined regulatory procedures for novel radiopharmaceuticals, such as those for cancer treatments.

Report Coverage

This research report categorizes the market for South Korea radiopharmaceuticals market based on various segments and regions forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea radiopharmaceuticals market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each South Korea radiopharmaceuticals market sub-segment.

Driving Factors

The market for radiopharmaceuticals is the rising prevalence of cancer, heart disease, and neurological illnesses worldwide. The diagnosis and treatment of these illnesses frequently include nuclear medicine techniques, which raises the need for radiopharmaceuticals. The need for radiopharmaceuticals is rising as such of ongoing developments in imaging technologies like PET and SPECT, which improve the accuracy and efficiency of diagnostic imaging. New radiotracers and radiopharmaceuticals are being developed as a result of increased investment in nuclear medicine research and development, improving patient outcomes and propelling market expansion.

Restraining Factors

Advanced facilities like nuclear reactors or cyclotrons, which are costly to construct and operate, are needed to produce radiopharmaceuticals. Highly skilled workers in radiation safety and nuclear medicine are required for the production and management of radioactive materials. Operating costs are raised by the need for stringent regulatory compliance and stringent quality control procedures for radiopharmaceuticals. Costs are further increased by the necessity for quick delivery and specialized storage due to the short half-lives of certain radioisotopes.

Market Segmentation

The South Korea radiopharmaceuticals market share is classified into type and application.

• The diagnostic segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korean radiopharmaceuticals market is segmented by type into diagnostic and therapeutic. Among these, the diagnostic segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Diagnostic radiopharmaceuticals are used extensively in a variety of imaging modalities, assisting medical practitioners in detecting illnesses early on, which is essential for the successful start of treatment. Compounds intended for nuclear imaging, which makes it easier to see physiological and metabolic processes in living things, are usually included in this group.

• The neurology segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea radiopharmaceuticals market is segmented by application into neurology, cardiology, oncology, and others. Among these, the neurology segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Neurology uses these substances to assess brain activity, greatly improving patient care for disorders like Parkinson's and Alzheimer's.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea radiopharmaceuticals market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Samyoung Unitech
• GE Healthcare
• FutureChem
• IBA Radiopharma Solutions
• NuCare Inc.
• DuChemBIO Co. Ltd
• KAERI (Korea Atomic Energy Research Institute)
• KIRAMS (Korea Institute of Radiological & Medical Sciences)
• Siemens Healthineers
• Genoray
• Posco Holdings
• Hanmi Pharmaceutical
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea radiopharmaceuticals market based on the below-mentioned segments:

South Korea Radiopharmaceuticals Market, By Type

• Diagnostic
• Therapeutic

South Korea Radiopharmaceuticals Market, By Application

• Neurology
• Cardiology
• Oncology
• Others